Rephine Group returns to CPHI Frankfurt, as a finalist for the Global Generics and Biosimilars Industry Partner of the Year award
- Rephine will be exhibiting & holding meetings at the Frankfurt event, November 1-3, in Hall 12, Stand C61. Client & Auditee Account Managers will be on hand throughout
- The Group will attend the prestigious Global Generics and Biosimilars awards ceremony at the event, as a finalist for Industry Partner of the Year
- 2022 has been a milestone year for Rephine, boosted by strategic acquisition, territory expansion, a strengthened top team and new branding
Stevenage, Hertfordshire, October 13th, 2022 – Rephine Group, a firm of deeply experienced GMP auditors specialising in pharmaceutical supply-chain quality assurance, has confirmed its return to this year’s Convention on Pharmaceutical Ingredients (CPHI) event in Frankfurt, Germany, where it will attend the Global Generics and Biosimilars awards as a finalist for Industry Partner of the Year.
Rephine will be exhibiting and holding meetings at the Frankfurt event from November 1-3 (Hall 12, Stand C61). Client & Auditee Account Managers will be on hand throughout, to update pharma and biotech companies on the Group’s expanded proposition, including its extensive audit library.
The Group is celebrating a milestone year in 2022 which has seen its library of live GMP audit reports swell to over 750, among other strategic developments that have cemented the company’s position as the go-to global provider of GMP compliance support.
Its market leadership was boosted in June by the acquisition of Barcelona-based GxP audit organisation Forum Auditorias and its technology and manufacturing supply chain compliance consultancy TDV (together known as AFA/TDV Group). The expanded Rephine organisation, with 100+ full-time employees and coverage of over 100 countries, now boasts a live, current audit report library spanning more than 2,500 pharma products.
Since the peak of the COVID-19 pandemic, the option to buy valid pre-existing reports has soared in popularity, as a cost-effective and convenient means to fulfil EU quality/QP requirements. Over the past 12 months, Rephine has seen demand for these reports continue to rise sharply, with 98% of clients returning to the resource. Numbers of new commissioned audits, meanwhile, have more than doubled over the last two years, to around 100.
The acquisition of AFA/TDV also extends Rephine’s offerings via TDV’s specialist manufacturing supply chain compliance consultancy services. These help pharma manufacturers achieve their GxP compliance goals through Quality by Design; Risk Management; and Pharma QMS to drive innovation and best-practice process efficiency as well as regulatory adherence.
Rephine has also bolstered its top team with a series of strategic promotions and new hires over the last year, as well as senior executives from the Spanish business and its Shanghai location.
Of Rephine’s participation at CPHI 2022 in Frankfurt, CEO Adam Sherlock said: “We’re thrilled to be returning to this important event, and to know that we will see so many attendees in person this year. We’re excited at the prospect of all of the topical conversations that will be struck up, and that face-to-face networking which is so crucial in a fast-moving industry like this.”
He continued: “To be a finalist for the Global Generics and Biosimilars Industry Partner of the Year award is the icing on the cake after a phenomenal year for our company. This has been and continues to be an incredible period of growth and strategic development for Rephine, in spite of challenging market conditions. Our ability to anticipate the evolving needs of our clients and auditees during this time has served the market well. Today we are ideally positioned to meet a whole spectrum of requirements for our clients, through an unbeatable set of solutions.”
The Global Generics & Biosimilars Awards recognise the off-patent pharmaceutical industry’s greatest achievements, including industry partners. Rephine has been shortlisted in the Industry Partner of the Year category. Winners will be announced at the Awards ceremony and cocktail reception on the evening of Wednesday 2nd November at the Frankfurt Marriott Hotel.
Rephine is a firm of deeply experienced GMP auditors which proactively help pharmaceutical companies around the world with their supply-chain quality assurance. As well as conducting audits on an as-needed basis, Rephine offers the single largest repository of live reports (within three-year validity), spanning thousands of individual products. More at rephine.com
Press contact for Rephine
Carina Birt, Sarum PR, 07970 006624, [email protected]